What are the recommended assessments and management steps for a patient with liver cirrhosis, including evaluation of etiology, prophylaxis for portal hypertension, treatment of ascites and hepatic encephalopathy, variceal bleeding prevention, and hepatocellular carcinoma surveillance?

Management of Liver Cirrhosis

Patients with newly diagnosed liver cirrhosis require immediate assessment of etiology, initiation of non-selective beta-blockers (carvedilol preferred) for portal hypertension prophylaxis if clinically significant portal hypertension is present, endoscopic screening for varices, hepatocellular carcinoma surveillance every 6 months, and evaluation for liver transplantation if decompensation occurs.

Initial Assessment and Etiology Evaluation

Upon diagnosis of cirrhosis, determine the underlying cause through:

• Alcohol use history (accounts for ~45% of cases) 1
• Metabolic dysfunction-associated steatotic liver disease screening (26% of cases) 1
• Hepatitis C and B serologies (hepatitis C accounts for 41% of cases) 1
• Autoimmune markers if indicated
• Liver stiffness measurement (LSM) via elastography - values ≥15 kPa typically confirm cirrhosis 1

Critical point: Approximately 40% of patients are diagnosed only when presenting with complications like ascites or hepatic encephalopathy, which carry median survival times of only 1.1 and 0.92 years respectively 1. Early identification is therefore crucial.

Portal Hypertension and Variceal Bleeding Prevention

Primary Prophylaxis (Preventing First Bleed)

For patients with medium/large varices:

• Non-selective beta-blockers are first-line therapy 2
• Carvedilol or propranolol should be initiated and titrated to maximum tolerated dose 2, 1
• In a 3-year trial of 201 patients, NSBBs reduced decompensation or death from 27% to 16% 1
• Alternative: Endoscopic variceal ligation (EVL) can be used if NSBBs are contraindicated 2

For patients with HCC and LSM ≥25 kPa:

• Start NSBBs without performing endoscopy first 3

Endoscopic Surveillance

Perform upper endoscopy at diagnosis to screen for varices 4. The annual incidence of varices in cirrhotic patients without baseline varices is 5-9% at 1 year 4.

Acute Variceal Bleeding Management

When active bleeding occurs, implement the following simultaneously:

1. Vasoactive drugs (somatostatin, octreotide, or terlipressin) - start immediately and continue 3-5 days 2
2. Antibiotic prophylaxis - oral norfloxacin 400mg BID or IV ciprofloxacin; in advanced cirrhosis use IV ceftriaxone 1g/day due to quinolone resistance 2
3. Endoscopy within 12 hours - perform EVL (preferred) or sclerotherapy 2
4. Maintain hemoglobin at 8 g/dL - avoid over-transfusion 2

For high-risk patients (Child-Pugh 10-13 or 8-9 with active bleeding at endoscopy):

• Preemptive TIPS within 72 hours significantly improves survival 5, 6

If bleeding cannot be controlled:

• Balloon tamponade as bridge (maximum 24 hours) 2
• Salvage TIPS 2

Secondary Prophylaxis (Preventing Rebleeding)

After surviving variceal hemorrhage, combination therapy is mandatory 2:

1. Non-selective beta-blockers (adjust to maximum tolerated dose) PLUS
2. Endoscopic variceal ligation - repeat every 1-2 weeks until obliteration 2
3. Surveillance endoscopy at 1-3 months post-obliteration, then every 6-12 months 2

This combination is superior to either therapy alone and represents the best option for secondary prophylaxis 2.

TIPS consideration: Reserve for Child-Pugh A or B patients with recurrent bleeding despite combination therapy 2. While TIPS reduces rebleeding more effectively than endoscopic therapy, it increases encephalopathy risk and does not improve survival 7.

Ascites Management

Initial Treatment

For new-onset ascites, perform diagnostic paracentesis immediately 8, 9:

• Test for SAAG (≥1.1 g/dL confirms portal hypertension), cell count, Gram stain, and culture 8
• Paracentesis within 12-24 hours of admission reduces hospital mortality 8

First-line therapy consists of 8, 10:

1. Sodium restriction to 2000 mg/day (88 mmol/day)
2. Spironolactone 100 mg daily (range 50-400 mg)
3. Furosemide 40 mg daily (range 20-160 mg) in 40:100 ratio with spironolactone

Target weight loss: 0.5 kg/day without edema; 1 kg/day with peripheral edema 8.

Fluid restriction is unnecessary unless serum sodium <120-125 mmol/L 10.

Large Volume Paracentesis

For tense ascites:

• Perform initial therapeutic paracentesis followed by diuretics 10
• Albumin infusion (8 g/L of ascites removed) is mandatory after paracentesis >5L 11
• For paracentesis <5L, consider albumin in patients with acute-on-chronic liver failure or high AKI risk 11

Refractory Ascites

Defined as unresponsive to maximum diuretics (400 mg spironolactone + 160 mg furosemide) or rapid recurrence 10.

Management options:

1. TIPS should be considered - improves outcomes in appropriate candidates 11
2. Exercise caution if: age >70 years, bilirubin >50 μmol/L, platelets <75×10⁹/L, MELD ≥18, current encephalopathy, active infection, or hepatorenal syndrome 11
3. Serial therapeutic paracenteses if TIPS contraindicated
4. Refer for liver transplantation evaluation 10, 9

Important: Refractory ascites is NOT a contraindication to NSBBs, but monitor closely and reduce/discontinue if hypotension or progressive renal dysfunction develops 11.

Spontaneous Bacterial Peritonitis (SBP)

Diagnosis: Ascitic fluid neutrophil count >250/mm³ 12.

Treatment 2:

• IV cefotaxime (empiric first-line)
• Albumin 1.5 g/kg within 6 hours of diagnosis, then 1 g/kg on day 3 - reduces mortality and prevents hepatorenal syndrome 11

Secondary prophylaxis after SBP episode:

• Long-term norfloxacin or trimethoprim/sulfamethoxazole 12

Primary prophylaxis:

• Norfloxacin in patients with ascitic fluid protein <1.5 g/dL 13

Hepatic Encephalopathy

Acute treatment and prevention of recurrence:

• Lactulose is first-line therapy - reduces mortality (8.5% vs 14% with placebo) and recurrent overt encephalopathy (25.5% vs 46.8%) 1
• Titrate to 2-3 soft bowel movements daily
• Rifaximin can be added for recurrent episodes
• Protein restriction is no longer recommended 12

Hepatocellular Carcinoma Surveillance

All cirrhotic patients require HCC screening 14:

• Ultrasound every 6 months with or without AFP
• Annual incidence is 1-4% in cirrhotic patients 1
• 5-year survival is only ~20% once HCC develops 1

Hepatorenal Syndrome

Treatment:

• Terlipressin improves reversal rate from 18% to 39% 1
• Albumin administration
• Median survival without treatment is <2 weeks 1

Liver Transplantation Evaluation

Refer for transplantation when:

• Development of ascites (reduces 5-year survival from 80% to 30%) 9
• Any decompensating event occurs 9
• Refractory ascites despite medical therapy 10
• Recurrent variceal bleeding despite optimal therapy 2

Common Pitfalls to Avoid

1. Do not use sclerotherapy for secondary prophylaxis - EVL is superior with fewer complications 2
2. Avoid NSAIDs - they convert diuretic-sensitive ascites to refractory 10
3. Do not over-transfuse during acute bleeding - target hemoglobin 8 g/dL 2
4. Do not restrict protein in hepatic encephalopathy - this outdated practice worsens outcomes 12
5. Do not delay TIPS in high-risk acute bleeders - preemptive TIPS within 72 hours improves survival 5
6. Do not withhold NSBBs in refractory ascites - monitor closely but continue if tolerated 11